Literature DB >> 597373

Pleural fluid complement, complement conversion, and immune complexes in immunologic and nonimmunologic diseases.

G G Hunder, F C McDuffie, K A Huston, L R Elveback, N G Hepper.   

Abstract

Forty-four pleural fluids and 41 blood specimens from patients with various diseases were examined for concentration of whole complement, C4, C3, conversion products of C3 and C3PA, and immune complexes. C3 conversion was found in all eight pleural fluids from patients with rheumatoid arthritis, five of seven with lupus erythematosus, two of six with congestive heart failure, and nine of 23 with malignant diseases. Conversion of C3PA correlated closely with C3 conversion and both were significantly inversely related to whole complement, C4, and C3. Concentration of immune complexes was highest in patients with rheumatoid arthritis. Pleural fluid immune complex concentrations correlated positively with conversion of C3 and C3PA. These findings suggest that the reduced levels of pleural fluid complement in rheumatoid arthritis and lupus erythematosus may be secondary to complement conversion by immune complexes.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 597373

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  11 in total

1.  BTS guidelines for the investigation of a unilateral pleural effusion in adults.

Authors:  N A Maskell; R J A Butland
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

Review 2.  Local immune responses in certain extra-articular manifestations of rheumatoid arthritis.

Authors:  J T Halla; R E Schrohenloher; W J Koopman
Journal:  Ann Rheum Dis       Date:  1992-05       Impact factor: 19.103

3.  A model of immune complex-mediated pleuropulmonary injury; evidence of deposition of circulating immune complexes in the lung.

Authors:  R L Kaplan; A L Schocket; T E King; R M Maulitz; J T Good; R E Stanford; S A Sahn
Journal:  Am J Pathol       Date:  1980-07       Impact factor: 4.307

4.  Refractory massive pleural effusion in systemic lupus erythematosus treated with talc poudrage.

Authors:  J L Kaine
Journal:  Ann Rheum Dis       Date:  1985-01       Impact factor: 19.103

5.  Chemical and immunological features of pleural effusions: comparison between rheumatoid arthritis and other diseases.

Authors:  T Pettersson; M Klockars; P E Hellström
Journal:  Thorax       Date:  1982-05       Impact factor: 9.139

6.  Pleural effusion: laboratory tests in 300 cases.

Authors:  A Hirsch; P Ruffie; M Nebut; J Bignon; J Chrétien
Journal:  Thorax       Date:  1979-02       Impact factor: 9.139

7.  Refractory massive pleural effusion in systemic lupus erythematosus treated by pleurectomy.

Authors:  J S Elborn; P Conn; S D Roberts
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

8.  Complement-fixing material in ther sera of patients with rheumatoid arthritis.

Authors:  F C McDuffie; G G Hunder; R J Clark
Journal:  Clin Exp Immunol       Date:  1978-05       Impact factor: 4.330

9.  High levels of complement breakdown products in tuberculous pleural effusions.

Authors:  D P Lew; L H Perrin; J D Vassalli; S Suter; P H Lambert; F A Waldvogel
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

10.  Decreased heat-labile opsonic activity and complement levels associated with evidence of C3 breakdown products in infected pleural effusions.

Authors:  P D Lew; R Zubler; P Vaudaux; J J Farquet; F A Waldvogel; P H Lambert
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.